<DOC>
	<DOC>NCT02581345</DOC>
	<brief_summary>The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.</brief_summary>
	<brief_title>Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1. Must be able to understand and communicate with the investigator and comply with the requirements of the study 2. Chronic plaquetype psoriasis diagnosed for at least 6 months before screening 3. Stable plaque psoriasis 4. History of receipt of or candidate for therapy. 5. Moderate to severe psoriasis at screening and baseline 6. Must be willing and able to selfadminister SC injections or have a caregiver available to administer injections 7. Male participants of childbearing potential must employ a highly effective contraceptive measure 8. Female participants must have a negative pregnancy test; are not planning to become pregnant; and must not be lactating. Female participants must also agree to employ a highly effective contraceptive measure. 1. Forms of psoriasis other than chronic plaquetype 2. Druginduced psoriasis. 3. Other skin conditions which would interfere with assessment of psoriasis 4. Medical conditions other than psoriasis for which systemic corticosteroids were used in the last year prior to screening 5. Other inflammatory conditions other than psoriasis or psoriatic arthritis 6. Prior use of systemic tumor necrosis factor (TNF) inhibitors, or 2 or more nonTNF biologic therapies 7. Ongoing use of prohibited psoriasis treatments 8. Ongoing use of other nonpsoriasis prohibited treatments 9. All other prior nonpsoriasis concomitant treatments must be on a stable dose for at least 4 weeks 10. Laboratory abnormalities at screening deemed clinically significant by the investigator 11. Any condition or illness which in the opinion of the investigator or sponsor poses an unacceptable safety risk 12. History of latex allergy 13. History of or current signs or symptoms or diagnosis of a demyelinating disorder 14. History of or current Class III or IV New York Heart Association congestive heart failure 15. Signs, symptoms, or diagnosis of lymphoproliferative disorders, lymphoma, leukemia, myeloproliferative disorders, or multiple myeloma 16. Current malignancy or history of any malignancy except adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ; no more than 3 lifetime basal cell and squamous cell carcinomas permitted 17. Chronic infections, recurrent infections; recent infection to be evaluated 18. History of or presence of human immunodeficiency virus (HIV), or Hepatitis B (HBV) or C virus (HCV) 19. History of active tuberculosis (TB) or untreated or inadequately treated latent TB. 20. Exposure to an investigational product ≤30 days prior to enrollment or participation in another clinical study during the course of this study 21. Participant is a family member or employee of the investigator or site staff or study team</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Moderate to severe chronic plaque psoriasis</keyword>
	<keyword>Psoriasis</keyword>
</DOC>